LABU240920C260000
- 0.02
- -0.10-83.33%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
What the Options Market Tells Us About Viking Therapeutics
TransDigm, BJ's Wholesale, AbbVie And More On CNBC's 'Final Trades'
Regeneron Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Reiterates Neutral on Gilead Sciences, Maintains $70 Price Target
Gilead Sciences Analyst Ratings
Court Finds United Therapeutics' Interference With Launch of Generic Treprostinil Injection Caused Losses Of More Than $137M
Exas Science Shares Are Trading Higher After the Company Announced Data for Its Blood-based Colorectal Cancer Screening Test.
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
Do Queasy Side Effects Mean the End of Weight-loss Drug Stock Hype?
Regeneron Pharmaceuticals And Sanofi Announce FDA Approval For Dupixent In The U.S. As First And Only Treatment For Adolescents With Chronic Rhinosinusitis With Nasal Polyps
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Natera Analyst Ratings
Kiniksa Draws Buy at Jefferies on Potential Blockbuster Status for Lead Drug
Marengo Therapeutics Enters Clinical Study Collaboration And Supply Agreement With Gilead Sciences
US stocks closed: Technology breaks through to lift the index, Nasdaq and S&P jointly achieve four consecutive gains.
① After four consecutive days of gains, the S&P 500 index is still 1.3% away from its historical high. ② Warren Buffett's deputy sold more than half of Berkshire Hathaway's positions, causing the stock price to fall for the seventh consecutive day. ③ AirPods Pro transforms into an OTC hearing aid, with FDA approval for Apple's hearing assistance software. ④ Gilead's HIV prevention drug delivers positive results once again.
Gilead Sciences Goes Ex-dividend Tomorrow
Cracking The Code: Understanding Analyst Reviews For Exact Sciences
What the Options Market Tells Us About Gilead Sciences
Gilead Posts Second Late-stage Win for Twice-yearly HIV Therapy
Gilead Shares Are Trading Higher After the Company Announced Interim Results From a Phase 3 Trial Showing That Twice-yearly Lenacapavir Reduced HIV Infections by 96%.